☆ 4.0 Article

Gene therapy in neuromuscular disorders

ARQUIVOS DE NEURO-PSIQUIATRIA (2022)

Related references

Note: Only part of the references are listed.

Article Pediatrics

Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study

Claudia Weiss et al.

Summary: This study provides real-world data on motor function and safety after gene replacement therapy in different patient subgroups. The results indicate that children with spinal muscular atrophy aged 24 months or younger and patients pretreated with nusinersen significantly benefit from gene replacement therapy, but adverse events can be severe and need to be closely monitored.

LANCET CHILD & ADOLESCENT HEALTH (2022)

Add to Collection

Review Pediatrics

Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy

Nicolas J. Abreu et al.

Summary: Both 5q-linked SMA and DMD are fatal monogenic neuromuscular disorders caused by loss-of-function mutations. Gene replacement therapy and antisense nucleotide-mediated therapies offer hopeful prospects for the treatment of these diseases.

PEDIATRIC PULMONOLOGY (2021)

Add to Collection

Article Clinical Neurology

Gene Therapy for Duchenne Muscular Dystrophy

Nertiyan Elangkovan et al.

Journal of Neuromuscular Diseases (2021)

Add to Collection

Article Clinical Neurology

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial

Eugenio Mercuri et al.

Summary: The STR1VE-EU study evaluated the safety and efficacy of onasemnogene abeparvovec gene replacement therapy in infants with spinal muscular atrophy type 1, showing effectiveness in symptomatic patients and a favorable benefit-risk profile for this patient population. Further long-term safety studies are needed.

LANCET NEUROLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy

Deepa Chand et al.

Summary: This study focuses on the risk of liver injury associated with OA in the treatment of SMA and provides guidance on its management. Analysis of data from 325 patients receiving OA treatment showed elevated liver function test results in some patients. Most patients mitigated these adverse effects through prophylactic prednisolone treatment.

JOURNAL OF HEPATOLOGY (2021)

Add to Collection

Article Pediatrics

Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series

Deepa H. Chand et al.

Summary: Spinal muscular atrophy is treated with onasemnogene abeparvovec, but it can lead to drug-induced thrombotic microangiopathy in some infants. Early recognition and treatment of this complication may reduce mortality and morbidity.

JOURNAL OF PEDIATRICS (2021)

Add to Collection

Article Clinical Neurology

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial

John W. Day et al.

Summary: The study evaluated the safety and efficacy of onasemnogene abeparvovec gene therapy in symptomatic patients with infantile-onset spinal muscular atrophy. Results showed that patients achieved independent sitting and survival rates without permanent ventilation at certain time points, with a favorable benefit-risk profile supporting the use of onasemnogene abeparvovec for treatment of this condition.

LANCET NEUROLOGY (2021)

Add to Collection

Review Biotechnology & Applied Microbiology

Gene therapy for ALS: A review

Defne A. Amado et al.

Summary: ALS has historically been challenging for gene therapy due to a lack of therapeutic targets and difficulty accessing the brain and spinal cord. Recent advances in disease mechanism understanding, ALS genetics, and CNS targeting, along with progress in gene delivery and editing techniques, have opened new therapeutic possibilities. Gene therapy clinical trials are underway for ALS patients with various genetic mutations, showing potential for disease-modifying treatment.

MOLECULAR THERAPY (2021)

Add to Collection

Article Neurosciences

Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit

Meaghan Van Alstyne et al.

Summary: This study demonstrates that long-term use of AAV9-SMN gene therapy in mice can lead to motor dysfunction and neuronal loss through protein aggregation. Overexpression of SMN interferes with RNA regulation and triggers SMA-like pathogenic events through toxic gain-of-function mechanisms. These findings suggest caution in the long-term safety of treating individuals with SMA with AAV9-SMN.

NATURE NEUROSCIENCE (2021)

Add to Collection

Article Clinical Neurology

Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy

Jerry R. Mendell et al.

Summary: This ongoing study evaluates the long-term safety and effectiveness of onasemnogene abeparvovec gene replacement therapy in infants with SMA type 1. The therapeutic dose showed sustained clinical benefits for patients with no need for permanent ventilation up to 6 years of age.

JAMA NEUROLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Viral vector platforms within the gene therapy landscape

Jote T. Bulcha et al.

Summary: The field of gene therapy has made significant progress in combating human diseases and providing hope to patients and families with limited treatment options, but it has also faced setbacks. Viral-based vectors have played a crucial role in developing powerful drug platforms, but challenges still limit their full potential.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

Add to Collection

Review Pharmacology & Pharmacy

Onasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy

Debra Stevens et al.

ANNALS OF PHARMACOTHERAPY (2020)

Add to Collection

Article Clinical Neurology

European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy

Janbernd Kirschner et al.

EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2020)

Add to Collection

Editorial Material Biotechnology & Applied Microbiology

Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy

James M. Wilson et al.

HUMAN GENE THERAPY (2020)

Add to Collection

Article Clinical Neurology

Combination molecular therapies for type 1 spinal muscular atrophy

Yohei Harada et al.

MUSCLE & NERVE (2020)

Add to Collection

Article Medicine, General & Internal

SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS

Christian Mueller et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Pediatrics

Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes

Megan A. Waldrop et al.

PEDIATRICS (2020)

Add to Collection

Review Clinical Neurology

Advancements in AAV-mediated Gene Therapy for Pompe Disease

S. M. Salabarria et al.

JOURNAL OF NEUROMUSCULAR DISEASES (2020)

Add to Collection

Article Medicine, Research & Experimental

Intravenous Injection of an AAV-PHP.B Vector Encoding Human Acid α-Glucosidase RescuesBoth Muscle and CNS Defects in Murine Pompe Disease

Jeong-A Lim et al.

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2019)

Add to Collection

Article Pharmacology & Pharmacy

Onasemnogene Abeparvovec: First Global Approval

Sheridan M. Hoy

DRUGS (2019)

Add to Collection

Review Clinical Neurology

From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1

Samiah A. Al-Zaidy et al.

PEDIATRIC NEUROLOGY (2019)

Add to Collection

Article Clinical Neurology

AVXS-101 (Onasemnogene Abeparvovec) for SMA 1: Comparative Study with a Prospective Natural History Cohort

Samiah A. Al-Zaidy et al.

JOURNAL OF NEUROMUSCULAR DISEASES (2019)

Add to Collection

Review Neurosciences

Therapeutic advances in 5q-linked spinal muscular atrophy

Umbertina Conti Reed et al.

ARQUIVOS DE NEURO-PSIQUIATRIA (2018)

Add to Collection

Review Clinical Neurology

Pompe Disease: From Basic Science to Therapy

Lara Kohler et al.

NEUROTHERAPEUTICS (2018)

Add to Collection

Article Cell Biology

Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques

Florie Borel et al.

SCIENCE TRANSLATIONAL MEDICINE (2018)

Add to Collection

Article Biotechnology & Applied Microbiology

Systemic AAV8-Mediated Gene Therapy Drives Whole-Body Correction of Myotubular Myopathy in Dogs

David L. Mack et al.

MOLECULAR THERAPY (2017)

Add to Collection

Article Medicine, General & Internal

Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy

J. R. Mendell et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy

R. S. Finkel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Multidisciplinary Sciences

Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy

Caroline Le Guiner et al.

NATURE COMMUNICATIONS (2017)

Add to Collection

Article Medicine, Research & Experimental

A Five-Repeat Micro-Dystrophin Gene Ameliorated Dystrophic Phenotype in the Severe DBA/2J-mdx Model of Duchenne Muscular Dystrophy

Chady H. Hakim et al.

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2017)

Add to Collection

Review Biochemistry & Molecular Biology

Viral vectors for gene therapy: Current state and clinical perspectives

A. N. Lukashev et al.

BIOCHEMISTRY-MOSCOW (2016)

Add to Collection

Article Biotechnology & Applied Microbiology

Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1(G93A) Mice and Nonhuman Primates

Florie Borel et al.

HUMAN GENE THERAPY (2016)

Add to Collection

Article Multidisciplinary Sciences

Gene therapy rescues disease phenotype in a spinal muscular atrophy with respiratory distress type 1 (SMARD1) mouse model

Monica Nizzardo et al.

SCIENCE ADVANCES (2015)

Add to Collection

Article Biotechnology & Applied Microbiology

Adenovirus: The First Effective In Vivo Gene Delivery Vector

Ronald G. Crystal

HUMAN GENE THERAPY (2014)

Add to Collection

Article Clinical Neurology

Observational study of spinal muscular atrophy type I and implications for clinical trials

Richard S. Finkel et al.

NEUROLOGY (2014)

Add to Collection

Review Biochemistry & Molecular Biology

Spinal muscular atrophy: going beyond the motor neuron

Gillian Hamilton et al.

TRENDS IN MOLECULAR MEDICINE (2013)

Add to Collection

Article Biochemistry & Molecular Biology

Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice

Elisa Dominguez et al.

HUMAN MOLECULAR GENETICS (2011)

Add to Collection

Article Biochemistry & Molecular Biology

SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments

Peter I. Joyce et al.

MAMMALIAN GENOME (2011)

Add to Collection

Article Cell Biology

Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy

Marco A. Passini et al.

SCIENCE TRANSLATIONAL MEDICINE (2011)

Add to Collection

Review Genetics & Heredity

Production, Purification and Characterization of Adeno-Associated Vectors

Eduard Ayuso et al.

CURRENT GENE THERAPY (2010)

Add to Collection

Review Pharmacology & Pharmacy

Viral vectors: from virology to transgene expression

D. Bouard et al.

BRITISH JOURNAL OF PHARMACOLOGY (2009)

Add to Collection

Article Virology

Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors

AK Zaiss et al.

JOURNAL OF VIROLOGY (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.